Synthetically Accessible Virtual Inventory (SAVI)

可综合访问的虚拟库存 (SAVI)

• 批准号: 10262390
• 负责人: MARC NICKLAUS
• 金额: $ 44.92万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10262390
• 关键词: 2019-nCoV; Address; Behavior; Businesses; CCR; Chemicals; Chemistry; Clinical; Clinical Research; Collaborations; Custom; Data; Databases; Development; Docking; Drug Design; Equipment and supply inventories; Future; Generations; Germany; Goals; Growth; Intelligence; International; Internet; Language; Link; Malignant Neoplasms; Methyltransferase; Modeling; Molecular; Nucleocapsid; Outcome; Pattern; Pilot Projects; Predictive Cancer Model; Price; Process; Production; Property; Publications; Publishing; Reaction; Resources; Route; Running; Sampling; Services; Structure; Systems Biology; Work; Writing; base; cancer initiation; computer generated; cost effective; drug candidate; drug development; endonuclease; functional group; in silico; knowledge base; new therapeutic target; novel; novel therapeutics; screening; tumor; virtual; web server

The SAVI Project is based on: (a) a set of transforms with rich chemical context annotation including functional group reactivity data (LHASA, LLC, U.S.; and Lhasa Limited, UK) (b) a set of highly annotated building blocks (Sigma-Aldrich, Global Strategic Services) (c) the chemoinformatics toolkit CACTVS with custom development (Xemistry GmbH, Germany) The transforms are a set of more than 1,500 rules described in the CHMTRN/PATRAN language for encoding chemical transformations with chemical context and quality criteria added, based ultimately on the pioneering work of E. J. Corey. These rules, in contrast to simple SMIRKS transforms, allow/provide: - Computation of whether a reaction, depending on the overall structural features of the target, will work at all. - Scoring: If the reaction works, how robust it is, taking into account overall structural features. - Whether protection of interfering groups is required - and these can then already be integrated in the final starting materials queries to prioritize pre-protected starting materials. - Proposal of suitable context-dependent reaction conditions. - Textual warnings in specific circumstances, such as potential of multiple products, borderline conditions, etc. Ancillary information to the rules is a set of functional group reactivity data, i.e. a table describing whether any of the standard functional groups in the rule set is unstable under any of the standard conditions. The building blocks are a set of several hundred thousand compounds available in gram quantities, and with high reliability, from, or through, Sigma-Aldrich. This set has been annotated with pricing information and other business intelligence type data useful for this project. The chemoinformatics toolkit CACTVS has been expanded in various ways, e.g. with the capability to read the CHMTRN/PATRAN transforms. An important feature that needed to be implemented was the handling of the reversal of the original LHASA transform direction, without re-writing rules, for the strictly forward-synthetic SAVI project. Another important capability was the initial and final starting material (SM) query handling, i.e. the 4-steps: initial SM query extraction from the 2D patterns in the rules; forward reaction from the 2D patterns; scoring (which is the only original LHASA functionality); final SM query expansion (R-groups, protecting groups, etc.). For the goal of filtering out structures with less-than-desirable attributes in the drug development context, several additional computed properties regarded as important in current drug design have been implemented, such as the demerit scores based on 275 rules for identifying potentially reactive or promiscuous compounds, published by Bruns and Watson (J. Med. Chem. 2012, 55, 9763?9772); dx.doi.org/10.1021/jm301008n. In the current, very early alpha, stage of this project, only 11 transforms of the possible 1,500 were used; applied to approx. 230,000 building blocks; in only one-step reactions. The 610,000 resulting products have been annotated but not yet filtered with any of the computed or associated molecular properties. To limit the file size, only on the order of one percent of the theoretically possible products (of one-step reactions) was sampled. We have addressed the task of generating schematic graphical representations of the transforms. We are ultimately aiming at creating a database of one billion high-quality screening samples that should be easily and cheaply synthesizable. Our first full production run, using 14 transforms and about 377,000 building blocks, has resulted in more than 236 million products. These novel molecules are all annotated with a proposed simple and high-yield synthetic route, as well as by 50 molecular properties generally recognized as important in cutting-edge drug design that we have implemented. A web GUI is planned that will allow users free access to this database via searches by various criteria including substructure searches. It will also present links to pages where users can place requests for having the molecule(s) synthesized by commercial entities. Additional novel transforms for chemistry heretofore not in the knowledgebase have been written, yielding a total of over 70 productive and drafted transforms. After a change in the business model of Sigma-Aldrich, we decided to change the set of building blocks to Enamine, from whom we got about 151,000 possible structures. With 143,000 of those matching the 53 productive transforms used, we finished calculating 1.75 billion SAVI products in early 2020. We have made them publicly available for download on the CADD Group's web server at https://doi.org/10.35115/37N9-5738. A publication about the SAVI project is available as a preprint at https://doi.org/10.26434/chemrxiv.12185559.v1. CCR colleagues are using the SAVI database to screen for docking against the following SARS-CoV-2 targets: NSP7, NSP8, NSP9, NSP10, NSP15 (endonuclease), NSP16 (methyltransferase), Spike RBD, Nucleocapsid.

The SAVI Project is based on: (a) a set of transforms with rich chemical context annotation including functional group reactivity data (LHASA, LLC, U.S.; and Lhasa Limited, UK) (b) a set of highly annotated building blocks (Sigma-Aldrich, Global Strategic Services) (c) the chemoinformatics toolkit CACTVS with custom development (Xemistry GmbH, Germany) The transforms are a set CHMTRN/Patran语言中描述的1,500多个规则，用于用化学背景和质量标准编码化学转化，最终基于E. J. Corey的开拓性工作。这些规则与简单的假笑声相反，允许/提供： - 计算反应是否取决于目标的整体结构特征，完全可以起作用。 - 评分：如果反应起作用，则考虑到整体结构特征。 - 是否需要保护干涉组 - 然后可以将这些保护组集成到最终的起始材料查询中，以优先考虑预先保护的起始材料。 - 适当依赖上下文反应条件的建议。 - 在特定情况下的文本警告，例如多种产品的潜力，边界条件等。规则的辅助信息是一组功能组反应性数据，即描述规则集中的任何标准功能组在任何标准条件下是否不稳定。构建块是数十万种化合物的集合，可提供革兰氏数量，并且具有很高的可靠性，从或通过Sigma-Aldrich。该集合已注明了定价信息和其他对该项目有用的商业智能类型数据。化学信息学工具包CACTV已通过各种方式扩展，例如具有阅读CHMTRN/Patran变换的能力。需要实施的一个重要功能是处理原始的LHASA变换方向的逆转，而无需重新编写规则，即严格的前向合成的SAVI项目。另一个重要功能是初始和最终的起始材料（SM）查询处理，即4步：从规则中的2D模式中提取初始SM查询； 2D模式的正向反应；评分（这是唯一的原始LHASA功能）；最终的SM查询扩展（R组，保护组等）。为了使在药物开发环境中过滤质量不足的属性过滤结构，已经实施了几种在当前药物设计中被认为很重要的计算特性，例如基于275种识别潜在反应性或滥交化合物的规则的Demerit得分，Bruns和Watson（J. Med。Chem。Chem。Chem。Chem。2012，55，977,977,9772）; dx.doi.org/10.1021/jm301008n。在该项目的当前非常早的α阶段，仅使用了11个可能的1,500个变换。应用于大约。 230,000个构件；仅在一步反应中。已有610,000个产生的产品被注释但尚未用任何计算的或相关的分子特性过滤。为了限制文件大小，仅根据理论上可能（一步反应）的1％的订单进行采样。我们已经解决了生成转换的示意图图形表示的任务。我们最终旨在创建一个十亿高质量筛查样本的数据库，该样本应该容易且便宜地合成。我们使用14个变换和约377,000个构建块的首次完整生产运行，产生了超过2.36亿种产品。这些新型分子均以所提出的简单和高收益合成途径以及50个分子特性进行注释，通常在我们实施的尖端药物设计中被认为很重要。计划了Web GUI，该Web将允许用户通过包括子结构搜索在内的各种标准通过搜索免费访问此数据库。它还将介绍到网页的链接，用户可以在其中提出请求，以使商业实体合成分子。在知识库中，还没有编写其他新的化学变换，总共产生了70多种生产和起草的变换。在改变了Sigma-Aldrich的业务模型之后，我们决定将构件集更改为Onamine，我们从中获得了约151,000个可能的结构。在2020年初，我们完成了与53种生产转换相匹配的人中有143,000个，我们完成了17.5亿SAVI产品的计算。我们已在CADD Group的Web服务器上公开下载，网址为https://doi.org/10.35115/37n9-5738。有关SAVI项目的出版物可作为预印本提供，网址为https://doi.org/10.26434/chemrxiv.121855559.v1。 CCR同事正在使用SAVI数据库来筛选以下SARS-COV-2目标：NSP7，NSP8，NSP9，NSP9，NSP10，NSP10，NSP15（内核酸酶），NSP16（NSP16），NSP16（甲基转移酶），Spike RBD，rbd，nucleocapsid。